

Format for ANSWERING REVIEWERS

October 19, 2014



Dear Editor,

Please find enclosed the edited manuscript in Word format (file name: 13653-review.doc).

Title: Diabetic cardiac autonomic neuropathy: do we have any treatment perspectives?

Author: Victoria A Serhiyenko, Alexandr A Serhiyenko

Name of Journal: *World Journal of Diabetes*

ESPS Manuscript NO: 13653

The manuscript has been improved according to the suggestions of reviewers:

1 Format has been updated

2 Revision has been made according to the suggestions of the reviewer

- (1) Physical activity may improve cardiovascular autonomic function? Please include some information in the review about this subject.
The appropriate information was included to the chapter Therapeutic approaches for CAN, section Lifestyle modification.
- (2) The English of the review should be very much improved; also there are many typing errors that should be corrected.
The typing errors were corrected, English was improved.
- (3) Page 11 - First paragraph: the references do not seem appropriate to what is written in the text.
Corrected.
- (4) Page 11 - There is a meta-analysis and review about aldolase reeducates inhibitors (Plos One), please include it in the text accordingly.
The meta-analysis about aldose reeducates inhibitors was included in the text.
- (5) Page 16 - Second paragraph - Despite foods containing alpha lipoic acid and ω -3 PUFA have been recommended as possible beneficial options, presently, evidence does not support recommended as possible beneficial options, presently, evidence does not support recommending any nutritional supplement for people with diabetes for the prevention or treatment of cardiovascular events and cardiovascular autonomic neuropathy. It is interesting to include this information in the text.
The effectiveness of the alpha lipoic acid in the treatment of diabetic polyneuropathy, in particular of CAN, has been proven in the numerous international multicentral trials. American Diabetes Association (ADA, 2005) recommend the prescription of α -LA and ω -3 PUFA in algorithms of DPN treatment and in ADA recommendations (2014) and results of some

trials-prescription of ω -3 PUFA in DLP treatment among patients with T2DM and cardiovascular diseases

- (6) Page 16 – Last paragraph “antihyperglycemic” treatment is better, it is not hypoglycemic therapy.
The term was corrected.
- (7) Page 17 – First paragraph: first line – please include the quantity of ω -3 PUFA in each capsule.
The quantity of the ω -3 PUFA was included.
- (8) Page 18 – What values were considered physiologic for arterial stiffness parameters? Please include reference values and the references accordingly.
The reference values for arterial stiffness parameters (according to the program orders) were included to the text.
- (9) Page 19 – First paragraph, second line – was not found...
Corrected
- (10) Page 20 – First paragraph: Reference 39 is not appropriate for the text.
Corrected.

3 References and typesetting were corrected

The changes to the manuscript were made according to the peer-reviewers comments and highlighted.

Thank you again for publishing our manuscript in the *World Journal of Diabetes*.

Sincerely yours,

Victoria A Serhiyenko, MD
Department of Endocrinology
National Medical University
named after Danylo Galytski
Lviv, 69 Pekarska Str.
79017 Ukraine
Fax: +380322769496
E-mail: serhiyenko@inbox.ru